Stakeholders ask for flexibility, more examples in FDA guidance on overall survival in cancer trials
Regulatory NewsFerdous Al-Faruque
GuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsFerdous Al-FaruqueGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)